Browse the evidence

Obesity-induced dysfunction of white adipose tissue (WAT) lipid sequestration capacity drives systemic insulin resistance by allowing toxic lipid accumulation in the liver and skeletal muscle, thereby increasing hepatic glucose output and impairing peripheral glucose disposal.

In obesity, the failure of fat cells to store fat safely leads to fat spilling into the liver and muscles, causing insulin resistance. Restoring the ability of adipose tissue to sequester lipids (e.g., through weight loss or specific metabolic therapies) is critical for resolving systemic insulin resistance, not just treating the liver or muscle directly.

Downregulation of specific adipokines (e.g., adiponectin, Neuregulin 4) and batokines (e.g., 12-HEPE, 12,13-diHOME) in obesity contributes to systemic insulin resistance by failing to suppress hepatic lipogenesis and promote peripheral glucose uptake.

Maintaining healthy adipose tissue function involves not just storage capacity but also the secretion of beneficial hormones. Obesity suppresses these protective factors (like Nrg4 and adiponectin), worsening insulin resistance. Weight loss and exercise can help restore these beneficial secretions.

Exercise-induced circadian phase shifts are not significantly different between young adults (18-30 years) and older adults (59-75 years), nor between men and women.

You do not need to adjust your exercise timing strategy based on your age or sex to achieve circadian phase shifts. The same timing principles apply to older adults as they do to younger adults.

Activation of the bile acid receptor TGR5 induces beige remodelling of white adipose tissue (scWAT) by promoting mitochondrial biogenesis and fission, thereby increasing energy expenditure and reducing adiposity.

This research identifies TGR5, a receptor activated by bile acids, as a key driver of fat-burning (beiging) in subcutaneous fat. While this is currently a pharmacological target (using mimetics like INT-777) in research, it suggests that dietary strategies influencing bile acid profiles or TGR5 activation could theoretically support metabolic health and fat loss by turning white fat into energy-expending beige fat.

Ghrelin is the only known orexigenic peptide hormone, stimulating food intake by activating NPY/AgRP neurons in the arcuate nucleus and inhibiting POMC neurons, with levels inversely correlated with body fat and meal status.

Ghrelin is your body's natural 'hunger hormone' released by the stomach when empty. Its levels drop after eating, signaling satiety. In obesity, baseline ghrelin levels are often lower, but sensitivity may be altered. Understanding this helps recognize that hunger is a physiological signal, not just a habit.

Anorexigenic gut hormones (GLP-1, PYY, CCK, PP, OXM) are released post-prandially in proportion to caloric intake and inhibit appetite via central (ARC) and peripheral (vagal) pathways.

After eating, your gut releases hormones like GLP-1 and PYY to tell your brain you are full. These levels rise with caloric intake. Eating protein-rich meals maximizes PYY release. Respecting these signals aids natural appetite control.

Leptin, secreted by adipose tissue, signals long-term energy stores to the brain, inhibiting NPY/AgRP neurons and activating POMC neurons to reduce food intake, with levels proportional to body fat.

Leptin is a hormone from fat cells that tells your brain about long-term energy stores. Higher body fat means higher leptin. It works by suppressing hunger neurons (NPY/AgRP) and activating satiety neurons (POMC) in the brain.

Low levels of IL-6 promote satellite cell activation and muscle regeneration, whereas chronically elevated IL-6 levels drive skeletal muscle wasting and cachexia.

Understand that muscle damage and the resulting inflammatory response (including IL-6) are not inherently bad; they are the signals required for muscle repair. However, chronic, unmanaged inflammation (often seen in disease) leads to wasting. Focus on resolving acute inflammation through recovery rather than suppressing all inflammatory markers, as some are necessary for growth.

Abnormalities in the enzymatic processing of the pro-opiomelanocortin (POMC) precursor in hypothalamic neurons critically disrupt the regulation of appetite, energy homeostasis, and body composition.

Understanding weight regulation requires looking beyond simple gene presence. If you have a genetic predisposition to obesity, it may not be just about 'having the gene' but about how your body processes hormones like POMC into active forms like alpha-MSH. This suggests that treatments targeting the processing enzymes (like PC2) or the hormone receptors themselves may be necessary for those with specific processing defects, rather than just focusing on caloric intake.

Selective beta-3 adrenergic receptor (beta3AR) agonists prevent or reverse obesity and stimulate thermogenesis in animal models by inducing brown adipocytes in white fat and increasing energy expenditure, independent of food intake.

This research highlights beta-3 adrenergic receptors as a key target for treating obesity by increasing energy expenditure (thermogenesis) rather than suppressing appetite. While effective in animals, human application is complicated by lower receptor density. Future treatments may require highly selective drugs to be effective in humans.

Obesity induces selective sympathetic nervous system (SNS) overactivity, particularly directed to muscle vasculature and kidneys, which contributes to cardiovascular risk (hypertension) but fails to increase energy expenditure or promote weight loss.

Understanding that obesity involves a specific type of nervous system stress (selective SNS activation) helps reframe the condition as a physiological state rather than just a willpower issue. While this state increases cardiovascular risk, it does not actively burn fat. Treatments targeting autonomic dysfunction (like weight loss itself) may reverse these alterations.

Selective leptin resistance in obesity preserves the sympathoexcitatory effects of leptin (increasing blood pressure) while blunting its appetite-suppressing effects.

In obesity, the body may become resistant to leptin's ability to tell you to stop eating, but it remains sensitive to leptin's ability to raise blood pressure. This explains why obese individuals often have high blood pressure even if they don't feel hungry.

Bariatric surgery induces weight loss primarily through the suppression of ghrelin, a hunger-stimulating hormone, rather than solely through malabsorption.

Bariatric surgery is effective not just because it physically restricts food intake, but because it alters gut hormones like ghrelin to reduce hunger signals. This hormonal shift helps maintain weight loss long-term, even after the initial physical restriction effects diminish.

Muscle-specific overexpression of either IGF-1Ea or IGF-1Eb isoforms counteracts age-related sarcopenia by activating autophagy and PGC-1α-mediated mitochondrial biogenesis, thereby preserving muscle mass, force, and neuromuscular junction integrity without systemic side effects.

This research suggests that maintaining local muscle production of specific IGF-1 isoforms (Ea and Eb) is crucial for fighting age-related muscle loss. While this study used genetic modification in mice, it highlights that local muscle health mechanisms (autophagy and mitochondrial function) are key targets for preventing sarcopenia, rather than just relying on systemic hormone levels.

NSAID use in T2DM patients significantly increases the risk of Acute Kidney Injury (AKI) and cardiovascular events, particularly when combined with antihypertensives or SGLT2 inhibitors.

Avoid oral NSAIDs (like ibuprofen or diclofenac) if you have diabetes, especially if you take blood pressure meds or SGLT2 inhibitors. They significantly raise your risk of kidney injury and heart issues. Use topical NSAIDs or acetaminophen (with liver caution) instead.

In nonalcoholic fatty liver disease (NAFLD), hepatic diacylglycerol (DAG) concentrations are increased and positively correlate with liver fat content, whereas ceramide concentrations remain unchanged and do not correlate with liver fat.

If you have fatty liver, the specific type of fat accumulating in your liver matters. This research suggests that diacylglycerols (DAGs), not ceramides, are the lipid species that rise alongside liver fat in humans. While this is a mechanistic finding, it implies that interventions targeting lipid metabolism should consider the specific lipid species involved rather than assuming all 'bad fats' act the same way.

Hepatic Stearoyl-CoA Desaturase 1 (SCD1) activity is significantly increased in human fatty liver and positively correlates with liver fat content and diacylglycerol concentrations.

High SCD1 activity is a hallmark of fatty liver in humans. This enzyme helps convert saturated fats into monounsaturated fats (like oleic acid). The study shows that as liver fat increases, SCD1 activity increases. This suggests that dietary fats high in saturated fatty acids might fuel this process, leading to more monounsaturated fats and subsequently more triglycerides/DAGs in the liver.

Forced expression of miR-196a in white adipose tissue progenitor cells induces metabolically functional brown adipocyte-like cells, leading to enhanced energy expenditure and resistance to obesity.

This research identifies a specific molecular pathway (miR-196a) that converts white fat into energy-burning brown fat-like cells. While not yet a direct human treatment, it suggests that future therapies targeting this pathway could help combat obesity by increasing energy expenditure without requiring extreme caloric restriction.

Regular exercise training (aerobic or strength) does not increase circulating irisin levels in healthy, untrained adults, contradicting the hypothesis that irisin mediates health-related training effects.

Do not expect exercise to work by spiking irisin levels. This study shows that while your fitness improves significantly (running faster, stronger), your blood irisin levels do not necessarily rise. Focus on the performance gains rather than looking for this specific hormonal marker.

Mutations in the MC4R gene are a significant cause of monogenic obesity, resulting in increased body weight, hyperphagia (larger meals), and potentially reduced energy expenditure, but not necessarily binge eating.

If you have an MC4R mutation, expect that you may naturally eat larger meals and potentially have a slightly lower energy expenditure. This is a biological trait, not a character flaw. Management strategies should focus on portion control and understanding satiety cues.

Chronically elevated insulin levels (hyperinsulinemia) directly cause obesity, cardiovascular disease, and reduced lifespan through selective signaling pathways that remain active despite insulin resistance.

To protect your long-term health, aim to keep your insulin levels low, not just your blood sugar. This means prioritizing a lifestyle that minimizes insulin spikes: limit refined carbohydrates and sugars, engage in regular physical activity to improve insulin sensitivity, and consider time-restricted eating to lower baseline insulin. If you have type 2 diabetes, discuss with your doctor whether treatments that lower insulin levels (like metformin or GLP-1 agonists) are preferable to those that simply lower glucose by increasing insulin secretion.

Overexpression of microRNA-29b (miR-29b) promotes skeletal muscle atrophy by directly targeting and suppressing IGF-1 and PI3K(p85a), thereby inhibiting the PI3K-AKT-mTOR signaling pathway and increasing the expression of atrogenes Atrogin-1 and Murf-1.

This research identifies miR-29b as a key molecular driver of muscle wasting in various conditions (aging, disease, inactivity). While this paper does not provide a direct lifestyle intervention, it highlights that suppressing miR-29b could theoretically protect against muscle loss. Current lifestyle interventions (resistance training, adequate protein) likely work, in part, by modulating these molecular pathways, though direct manipulation of miR-29b is not yet a standard practice.

Activation of Toll-Like Receptor 4 (TLR4) by endogenous ligands (saturated fatty acids) and exogenous ligands (gut-derived lipopolysaccharide) triggers pro-inflammatory signaling pathways (JNK, IKK, p38) that directly impair insulin signal transduction via inhibitory phosphorylation of insulin receptor substrate (IRS).

Insulin resistance is driven by inflammation triggered by specific dietary components and gut health. High intake of saturated fats and gut-derived endotoxins can activate immune receptors (TLR4) in your tissues, directly blocking insulin's ability to work. To improve insulin sensitivity, focus on reducing inflammatory triggers (like excessive saturated fats and processed foods that affect gut permeability) rather than just counting calories.

In very old community-living women, higher cellular production of Interleukin-6 (IL-6) is a significant predictor of sarcopenia (loss of fat-free mass), indicating a catabolic inflammatory process.

For older women, muscle loss may be driven by internal inflammatory processes (specifically cellular IL-6 production) rather than just diet or activity levels. This suggests that managing chronic low-grade inflammation and metabolic health is critical for preserving muscle mass. Regular health check-ups focusing on inflammatory markers might be more insightful than standard muscle mass tests alone.